Home › Funds › MONTANOVA CAPITAL, LLC › LXEO

MONTANOVA CAPITAL, LLC position in LXEO

LEXEO THERAPEUTICS INC COM · Health Care

MONTANOVA CAPITAL, LLC reported holding 6,384,200 shares of LXEO (LEXEO THERAPEUTICS INC COM) in its Q2 2026 13F filing — a position valued at US$29.7M, representing 0.54% of its reported portfolio and ranking #46 among its reported holdings. MONTANOVA CAPITAL, LLC has disclosed LXEO holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)6.38M sh
Reported value held$29.72M
Portfolio Weight0.54%
First reportedQ4 2025
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How MONTANOVA CAPITAL, LLC's LXEO position evolved

MONTANOVA CAPITAL, LLC first disclosed a stake in LXEO in Q4 2025 at 1,250,000 shares (US$12.4M). The position peaked in Q2 2026 at 6,384,200 shares, worth US$29.7M. Across 3 filings, MONTANOVA CAPITAL, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 6,384,200 shares valued at US$29.7M — an increase of 5,134,200 shares quarter over quarter.. Notable position changes include a 411% increase in Q2 2026 (shares fell 27% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 1.25M $12.41M New
Q1 2026 1.25M $7.17M Hold
Q2 2026 6.38M $29.72M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About LXEO and 13F data

LXEO (LEXEO THERAPEUTICS INC COM) is a Health Care company. 40 other funds we track also report a position in LXEO — the largest reported positions include Affinity Asset Advisors, LLC (US$27.0M), Frazier Life Sciences Management, L.P. (US$22.5M), Vestal Point Capital, LP (US$20.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding LXEO

All LXEO fund holders →

FAQ

How long has MONTANOVA CAPITAL, LLC held LXEO?

MONTANOVA CAPITAL, LLC has disclosed LXEO holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

What is MONTANOVA CAPITAL, LLC's current position in LXEO?

As of Q2 2026, MONTANOVA CAPITAL, LLC holds 6.38M shares of LXEO (LEXEO THERAPEUTICS INC COM), valued at $29.72M, representing 0.54% of its reported portfolio and ranking #46.

Has MONTANOVA CAPITAL, LLC been buying or selling LXEO?

In the latest 13F filing (Q2 2026), MONTANOVA CAPITAL, LLC increased its position in LXEO. The position peaked in Q2 2026 at 6.38M shares.

Which other funds hold LXEO?

Other major institutional holders of LXEO include Affinity Asset Advisors, LLC, Frazier Life Sciences Management, L.P., Vestal Point Capital, LP, among 40 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.